Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Mo | Alpha Teknova, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.05. | Alpha Teknova, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
08.05. | Alpha Teknova Q1 2025 slides: improved margins despite mixed revenue performance | 2 | Investing.com | ||
08.05. | Alpha Teknova GAAP EPS of -$0.09, revenue of $9.8M | 2 | Seeking Alpha | ||
25.04. | Alpha Teknova, Inc.: Teknova to Report First Quarter 2025 Financial Results on May 8, 2025 | 1 | GlobeNewswire (USA) | ||
19.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Launch Proprietary PluriFreeze Cryopreservation System to Accelerate the Development of Cell Therapies | 1 | GlobeNewswire (USA) | ||
ALPHA TEKNOVA Aktie jetzt für 0€ handeln | |||||
12.03. | Teknova and Pluristyx join hands to streamline next-generation cell therapy production | 3 | Seeking Alpha | ||
12.03. | Alpha Teknova, Inc.: Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies | 1 | GlobeNewswire (USA) | ||
07.03. | Alpha Teknova, Inc. - 10-K, Annual Report | - | SEC Filings | ||
05.03. | Alpha Teknova stock holds as KeyBanc maintains rating | 1 | Investing.com | ||
04.03. | Alpha Teknova, Inc. Q4 Loss Narrows | 1 | RTTNews | ||
04.03. | Alpha Teknova, Inc.: Teknova Reports Fourth Quarter and Full Year 2024 Financial Results | 416 | GlobeNewswire (Europe) | Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides... ► Artikel lesen | |
04.03. | Alpha Teknova, Inc. - 8-K, Current Report | - | SEC Filings | ||
20.02. | Alpha Teknova, Inc.: Teknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 | 1 | GlobeNewswire (USA) | ||
12.02. | Here's What Boosted Alpha Teknova (TKNO) in Q4 | 1 | Insider Monkey | ||
10.02. | Craig-Hallum initiates Alpha Teknova stock with buy rating | 1 | Investing.com | ||
09.07.24 | Alpha Teknova, Inc.: Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results | 470 | GlobeNewswire (Europe) | Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |